Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Walter Loos
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Disorders
Concepts & Ideas
Procedures
Phenomena
Sign-in to see full Profile
Network (preview)
86
Verweij, Jaap
59
Sparreboom, Alex
31
Nooter, Kees
28
Stoter, Gerrit
25
de Bruijn, Peter
22
de Jonge, M J A
15
Planting, A S T
15
Schellens, J H M
15
van der Burg, M E L
13
Brouwer, E
12
Mathijssen, Ron
10
Gelderblom, Hans
7
Engels, Frederike
6
de Jong, Floris
6
van Beurden, V
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Walter Loos (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: de Bruijn Peter; Moghaddam-Helmantel Inge M Ghobadi; de Jonge Maja J A; Meyer Thorsten; Lam Mei-Ho; Verweij Jaap; Wiemer Erik A C; Loos Walter J
Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry.
Journal of pharmaceutical and biomedical analysis 2009;50(5):977-82.
-
2009: Mom Constantijne H; Verweij Jaap; Oldenhuis Corina N A M; Gietema Jourik A; Fox Norma Lynn; Miceli Renée; Eskens Ferry A L M; Loos Walter J; de Vries Elisabeth G E; Sleijfer Stefan
Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(17):5584-90.
-
2009: Konings Inge R H M; Engels Frederike K; Sleijfer Stefan; Verweij Jaap; Wiemer Erik A C; Loos Walter J
Application of prolonged microdialysis sampling in carboplatin-treated cancer patients.
Cancer chemotherapy and pharmacology 2009;64(3):509-16.
-
2008: Lugtenberg Rieneke T; Cransberg Karlien; Loos Walter J; Wagner Anja; Alders Marielle; van den Heuvel-Eibrink Marry M
Topotecan distribution in an anephric infant with therapy-resistant bilateral Wilms tumor with a novel germline WT1 gene mutation.
Cancer chemotherapy and pharmacology 2008;62(6):1039-44.
-
2008: Heijns Joan B; van der Burg Maria E L; van Gelder Teun; Fieren Marien W J A; de Bruijn Peter; van der Gaast Ate; Loos Walter J
Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment.
Cancer chemotherapy and pharmacology 2008;62(5):841-7.
-
2007: Tascilar Metin; Loos Walter J; Seynaeve Caroline; Verweij Jaap; Sleijfer Stefan
The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas.
The oncologist 2007;12(11):1351-60.
-
2007: Loos W J; Zamboni W C; Engels F K; de Bruijn P; Lam M H; de Wit R; Verweij J; Wiemer E A C
Pitfalls of the application of microdialysis in clinical oncology: controversial findings with docetaxel.
Journal of pharmaceutical and biomedical analysis 2007;45(2):288-94.
-
2007: de Jong Floris A; van der Bol Jessica M; Mathijssen Ron H J; Loos Walter J; Mathôt Ron A A; Kitzen Jos J E M; van den Bent Martin J; Verweij Jaap
Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatotoxicity.
Cancer biology & therapy 2007;6(9):1368-74.
-
2007: Engels Frederike K; Loos Walter J; Mathot Ron A A; van Schaik Ron H N; Verweij Jaap
Influence of ketoconazole on the fecal and urinary disposition of docetaxel.
Cancer chemotherapy and pharmacology 2007;60(4):569-79.
-
2007: Mathijssen Ron H J; de Jong Floris A; Loos Walter J; van der Bol Jessica M; Verweij Jaap; Sparreboom Alex
Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?
The oncologist 2007;12(8):913-23.
-
2007: van der Bol Jessica M; Mathijssen Ron H J; Loos Walter J; Friberg Lena E; van Schaik Ron H N; de Jonge Maja J A; Planting André S Th; Verweij Jaap; Sparreboom Alex; de Jong Floris A
Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(19):2719-26.
-
2007: Engels Frederike K; de Jong Floris A; Sparreboom Alex; Mathot Ron A A; Loos Walter J; Kitzen Jos J E M; de Bruijn Peter; Verweij Jaap; Mathijssen Ron H J
Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel.
The oncologist 2007;12(3):291-300.
-
2007: Loos Walter J; de Wit Ronald; Freedman Steven J; Van Dyck Kristien; Gambale Jay J; Li Susie; Murphy Gail M; van Noort Connie; de Bruijn Peter; Verweij Jaap
Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.
Cancer chemotherapy and pharmacology 2007;59(3):407-12.
-
2006: Felici A; Loos W J; Verweij J; Cirillo I; de Bruijn P; Nooter K; Mathijssen R H J; de Jonge M J A
A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors.
Cancer chemotherapy and pharmacology 2006;58(5):673-80.
-
2006: Kitzen Jos J E M; Verweij Jaap; Wiemer Erik A C; Loos Walter J
The relevance of microdialysis for clinical on:cology.
Current clinical pharmacology 2006;1(3):255-63.
-
2006: de Jong Floris A; Kitzen Jos J E M; de Bruijn Peter; Verweij Jaap; Loos Walter J
Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain.
Cancer biology & therapy 2006;5(9):1105-10.
-
2006: Engels Frederike K; Mathot Ron A A; Loos Walter J; van Schaik Ron H N; Verweij Jaap
Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.
Cancer biology & therapy 2006;5(7):833-9.
-
2006: Loos Walter J; de Jongh Felix E; Sparreboom Alex; de Wit Ronald; van Boven-van Zomeren Desiree M; Stoter Gerrit; Nooter Kees; Verweij Jaap
Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(10):1499-506.
-
2006: Engels Frederike K; Buijs Dirk; Loos Walter J; Verweij Jaap; Bakker Willem H; Krenning Eric P
Quantification of [3H]docetaxel in feces and urine: development and validation of a combustion method.
Anti-cancer drugs 2006;17(1):63-7.
-
2005: Sparreboom Alex; Loos Walter J; Burger Herman; Sissung Tristan M; Verweij Jaap; Figg William D; Nooter Kees; Gelderblom Hans
Effect of ABCG2 genotype on the oral bioavailability of topotecan.
Cancer biology & therapy 2005;4(6):650-8.
-
2005: Scripture Charity D; Szebeni Janos; Loos Walter J; Figg William D; Sparreboom Alex
Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r).
Cancer biology & therapy 2005;4(5):555-60.
-
2004: de Jonge M J A; Kaye S; Verweij J; Brock C; Reade S; Scurr M; van Doorn L; Verheij C; Loos W; Brindley C; Mistry P; Cooper M; Judson I
Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours.
British journal of cancer 2004;91(8):1459-65.
-
2004: ten Tije Albert J; Loos Walter J; Zhao Ming; Baker Sharyn D; Enting Roelien H; van der Meulen Hans; Verweij Jaap; Sparreboom Alex
Limited cerebrospinal fluid penetration of docetaxel.
Anti-cancer drugs 2004;15(7):715-8.
-
2004: Engels Frederike K; Ten Tije Albert J; Baker Sharyn D; Lee Carlton K K; Loos Walter J; Vulto Arnold G; Verweij Jaap; Sparreboom Alex
Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.
Clinical pharmacology and therapeutics 2004;75(5):448-54.
-
2004: de Bruijn Peter; Willems Edwin W; Loos Walter J; Verweij Jaap; Sparreboom Alex
Indirect determination of the irinotecan metabolite 7-ethyl-10-O-glucuronyl-camptothecin in human samples.
Analytical biochemistry 2004;328(1):84-6.
-
2004: Soepenberg O; Sparreboom A; de Jonge M J A; Planting A S Th; de Heus G; Loos W J; Hartman C M; Bowden C; Verweij J
Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours.
European journal of cancer (Oxford, England : 1990) 2004;40(5):681-8.
-
2003: Ten Tije Albert J; Loos Walter J; Verweij Jaap; Baker Sharyn D; Dinh Kimberly; Figg William D; Sparreboom Alex
Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approaches.
Clinical pharmacology and therapeutics 2003;74(5):509-10.
-
2003: Loos Walter J; Baker Sharyn D; Verweij Jaap; Boonstra Joke G; Sparreboom Alex
Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins.
Clinical pharmacology and therapeutics 2003;74(4):364-71.
-
2003: de Jong Floris A; Mathijssen Ron H J; de Bruijn Peter; Loos Walter J; Verweij Jaap; Sparreboom Alex
Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;795(2):383-8.
-
2003: Gelderblom H; Loos W J; Sparreboom A; Soepenberg O; de Jonge M J A; van Boven-van Zomeren D M; Verweij J
Influence of the cisplatin hydration schedule on topotecan pharmacokinetics.
European journal of cancer (Oxford, England : 1990) 2003;39(11):1542-6.
-
2003: Loos Walter J; Gelderblom Hans; Verweij Jaap; van Boven-van Zomeren Desirée M; Nooter Kees; Stoter Gerrit; Sparreboom Alex
Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis.
Anti-cancer drugs 2003;14(3):227-32.
-
2003: ten Tije Albert J; Verweij Jaap; Loos Walter J; Sparreboom Alex
Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.
Clinical pharmacokinetics 2003;42(7):665-85.
-
2002: Mathijssen Ron H J; Verweij Jaap; de Bruijn Peter; Loos Walter J; Sparreboom Alex
Effects of St. John's wort on irinotecan metabolism.
Journal of the National Cancer Institute 2002;94(16):1247-9.
-
2002: Loos Walter J; Szebeni Janos; ten Tije Albert J; Verweij Jaap; van Zomeren Desirée M; Chung Kyu-nung; Nooter Kees; Stoter Gerrit; Sparreboom Alex
Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel.
Anti-cancer drugs 2002;13(7):767-75.
-
2002: Mathijssen R H J; Verweij J; Loos W J; de Bruijn P; Nooter K; Sparreboom A
Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38.
British journal of cancer 2002;87(2):144-50.
-
2002: Mathijssen Ron H J; Loos Walter J; Verweij Jaap; Sparreboom Alex
Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
Current cancer drug targets 2002;2(2):103-23.
-
2002: Loos Walter J; Verweij Jaap; Kehrer Diederik F S; de Bruijn Peter; de Groot Franciscus M H; Hamilton Marta; Nooter Kees; Stoter Gerrit; Sparreboom Alex
Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(3):856-62.
-
2002: Louwerens M; Smorenburg C; Sparreboom A; Loos W J; Verweij J; de Wit R
Phase I pharmacokinetic and sequence finding study of the combination of docetaxel and methotrexate in patients with solid tumours.
European journal of cancer (Oxford, England : 1990) 2002;38(4):497-504.
-
2002: Kehrer Diederik F S; Bos Annelies M; Verweij Jaap; Groen Harry J; Loos Walter J; Sparreboom Alex; de Jonge Maja J A; Hamilton Marta; Cameron Terri; de Vries Elisabeth G E
Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(5):1222-31.
-
2002: Schellens J H M; Heinrich B; Lehnert M; Gore M E; Kaye S B; Dombernowsky P; Paridaens R; van Oosterom A T; Verweij J; Loos W J; Calvert H; Pavlidis N; Cortes-Funes H; Wanders J; Roelvink M; Sessa C; Selinger K; Wissel P S; Gamucci T; Hanauske A R
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.
Investigational new drugs 2002;20(1):83-93.
-
2002: Loos Walter J; van Zomeren Desirée M; Gelderblom Hans; Verweij Jaap; Nooter Kees; Stoter Gerrit; Sparreboom Alex
Determination of topotecan in human whole blood and unwashed erythrocytes by high-performance liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2002;766(1):99-105.
-
2002: Gelderblom H; Loos W J; Verweij J; van der Burg M E L; de Jonge M J A; Brouwer E; Nooter K; Stoter G; Sparreboom A
Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies.
European journal of cancer (Oxford, England : 1990) 2002;38(1):205-13.
-
2001: Gelderblom H; Sparreboom A; de Jonge M J; Loos W J; Wilms E; Mantel M A; Hennis B; Camlett I; Verweij J; van der Burg M E
Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer.
British journal of cancer 2001;85(8):1124-9.
-
2001: de Jongh F E; Verweij J; Loos W J; de Wit R; de Jonge M J; Planting A S; Nooter K; Stoter G; Sparreboom A
Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(17):3733-9.
-
2001: Mathijssen R H; van Alphen R J; Verweij J; Loos W J; Nooter K; Stoter G; Sparreboom A
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2182-94.
-
2001: Schellens J H; Dombernowsky P; Cassidy J; Epelbaum R; Dirix L; Cox E H; Wanders J; Calabresi F; Paridaens R; Monfardini S; Wolff J; Loos W J; Verweij J; Pavlidis N; Hanauske A R;
Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9.
Anti-cancer drugs 2001;12(7):583-90.
-
2001: Kehrer D F; Soepenberg O; Loos W J; Verweij J; Sparreboom A
Modulation of camptothecin analogs in the treatment of cancer: a review.
Anti-cancer drugs 2001;12(2):89-105.
-
2000: Loos W J; Gelderblom H J; Verweij J; Brouwer E; de Jonge M J; Sparreboom A
Gender-dependent pharmacokinetics of topotecan in adult patients.
Anti-cancer drugs 2000;11(9):673-80.
-
2000: Brouwer E; Verweij J; De Bruijn P; Loos W J; Pillay M; Buijs D; Sparreboom A
Measurement of fraction unbound paclitaxel in human plasma.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(10):1141-5.
-
2000: Gelderblom A J; Loos W J; de Jonge M J; Sparreboom A; Planting A S; van der Burg M E; Brouwer E; Verheij C; Ouwens L; Hearn S; Verweij J
Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatin.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(9):1205-7.
-
2000: Loos W J; Gelderblom H; Sparreboom A; Verweij J; de Jonge M J
Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(7):2685-9.
-
2000: van Zuylen L; Gianni L; Verweij J; Mross K; Brouwer E; Loos W J; Sparreboom A
Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients.
Anti-cancer drugs 2000;11(5):331-7.
-
2000: Loos W J; de Bruijn P; Verweij J; Sparreboom A
Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography.
Anti-cancer drugs 2000;11(5):315-24.
-
2000: de Jonge M J; Loos W J; Gelderblom H; Planting A S; van der Burg M E; Sparreboom A; Brouwer E; van Beurden V; Mantel M A; Doyle E; Hearn S; Ross G; Verweij J
Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(10):2104-15.
-
2000: Gelderblom H; Loos W J; Verweij J; de Jonge M J; Sparreboom A
Topotecan lacks third space sequestration.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1288-92.
-
2000: Loos W J; Kehrer D; Brouwer E; Verweij J; de Bruijn P; Hamilton M; Gill S; Nooter K; Stoter G; Sparreboom A
Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 2000;738(1):155-63.
-
1999: Loos W J; de Bruijn P; van Zuylen L; Verweij J; Nooter K; Stoter G; Sparreboom A
Determination of 5-fluorouracil in microvolumes of human plasma by solvent extraction and high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1999;735(2):293-7.
-
1999: Sparreboom A; Loos W J; Nooter K; Stoter G; Verweij J
Liquid chromatographic analysis and preliminary pharmacokinetics of methotrexate in cancer patients co-treated with docetaxel.
Journal of chromatography. B, Biomedical sciences and applications 1999;735(1):111-9.
-
1999: Sparreboom A; Planting A S; Jewell R C; van der Burg M E; van der Gaast A; de Bruijn P; Loos W J; Nooter K; Chandler L H; Paul E M; Wissel P S; Verweij J
Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein.
Anti-cancer drugs 1999;10(8):719-28.
-
1999: Loos W J; Verweij J; Gelderblom H J; de Jonge M J; Brouwer E; Dallaire B K; Sparreboom A
Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans.
Anti-cancer drugs 1999;10(8):705-10.
-
1999: de Jonge M J; Punt C J; Gelderblom A H; Loos W J; van Beurden V; Planting A S; van der Burg M E; van Maanen L W; Dallaire B K; Verweij J; Wagener D J; Sparreboom A
Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(7):2219-26.
-
1999: Sparreboom A; de Jonge M J; Punt C J; Loos W J; Nooter K; Stoter G; Porro M G; Verweij J
Prediction of the systemic exposure to oral 9-amino-20(S)-camptothecin using single-sample analysis.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(7):816-20.
-
1999: de Jonge M J; Verweij J; Loos W J; Dallaire B K; Sparreboom A
Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva.
Clinical pharmacology and therapeutics 1999;65(5):491-9.
-
1999: van Zuylen L; Schellens J H; Goey S H; Pronk L C; de Boer-Dennert M M; Loos W J; Ma J; Stoter G; Verweij J
Phase I and pharmacologic study of the arotinoid Ro 40-8757 in combination with cisplatin and etoposide in patients with non-small cell lung cancer.
Anti-cancer drugs 1999;10(4):361-8.
-
1999: Sparreboom A; van Zuylen L; Brouwer E; Loos W J; de Bruijn P; Gelderblom H; Pillay M; Nooter K; Stoter G; Verweij J
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.
Cancer research 1999;59(7):1454-7.
-
1999: Mathijssen R H; van Alphen R J; de Jonge M J; Verweij J; de Bruijn P; Loos W J; Nooter K; Vernillet L; Stoter G; Sparreboom A
Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin.
Anti-cancer drugs 1999;10(1):9-16.
-
1999: Gerrits C J; Schellens J H; Burris H; Eckardt J R; Planting A S; van der Burg M E; Rodriguez G I; Loos W J; van Beurden V; Hudson I; Von Hoff D D; Verweij J
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(1):69-75.
-
1999: de Bruijn P; Verweij J; Loos W J; Kolker H J; Planting A S; Nooter K; Stoter G; Sparreboom A
Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography.
Analytical biochemistry 1999;266(2):216-21.
-
1998: Sparreboom A; de Jonge M J; de Bruijn P; Brouwer E; Nooter K; Loos W J; van Alphen R J; Mathijssen R H; Stoter G; Verweij J
Irinotecan (CPT-11) metabolism and disposition in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(11):2747-54.
-
1998: Sparreboom A; Verweij J; van der Burg M E; Loos W J; Brouwer E; Viganò L; Locatelli A; de Vos A I; Nooter K; Stoter G; Gianni L
Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(8):1937-42.
-
1998: Sparreboom A; de Jonge M J; Punt C J; Nooter K; Loos W J; Porro M G; Verweij J
Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(8):1915-9.
-
1998: Brouwer E; Verweij J; Hauns B; Loos W J; Nooter K; Mross K; Stoter G; Sparreboom A
Linearized colorimetric assay for cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions.
Analytical biochemistry 1998;261(2):198-202.
-
1998: Sparreboom A; de Bruijn P; de Jonge M J; Loos W J; Stoter G; Verweij J; Nooter K
Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces.
Journal of chromatography. B, Biomedical sciences and applications 1998;712(1-2):225-35.
-
1998: Gerrits C J; Burris H; Schellens J H; Planting A S; van den Burg M E; Rodriguez G I; van Beurden V; Loos W J; Hudson I; Fields S; Verweij J; von Hoff D D
Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.
European journal of cancer (Oxford, England : 1990) 1998;34(7):1030-5.
-
1998: Ma J; Maliepaard M; Nooter K; Loos W J; Kolker H J; Verweij J; Stoter G; Schellens J H
Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.
British journal of cancer 1998;77(10):1645-52.
-
1998: Gerrits C J; Burris H; Schellens J H; Eckardt J R; Planting A S; van der Burg M E; Rodriguez G I; Loos W J; van Beurden V; Hudson I; Fields S; Von Hoff D D; Verweij J
Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(5):1153-8.
-
1998: Sparreboom A; de Bruijn P; Nooter K; Loos W J; Stoter G; Verweij J
Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Biomedical sciences and applications 1998;705(1):159-64.
-
1998: Sparreboom A; Loos W J; Verweij J; de Vos A I; van der Burg M E; Stoter G; Nooter K
Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay.
Analytical biochemistry 1998;255(2):171-5.
-
1997: de Vos A I; Nooter K; Verweij J; Loos W J; Brouwer E; de Bruijn P; Ruijgrok E J; van der Burg M E; Stoter G; Sparreboom A
Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(11):1145-50.
-
1997: de Bruijn P; Verweij J; Loos W J; Nooter K; Stoter G; Sparreboom A
Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection.
Journal of chromatography. B, Biomedical sciences and applications 1997;698(1-2):277-85.
-
1997: Loos W J; Sparreboom A; Verweij J; Nooter K; Stoter G; Schellens J H
Determination of the lactone and lactone plus carboxylate forms of 9-aminocamptothecin in human plasma by sensitive high-performance liquid chromatography with fluorescence detection.
Journal of chromatography. B, Biomedical sciences and applications 1997;694(2):435-41.
-
1997: Loos W J; Verweij J; Nooter K; Stoter G; Sparreboom A
Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1997;693(2):437-41.
-
1997: Creemers G J; Gerrits C J; Eckardt J R; Schellens J H; Burris H A; Planting A S; Rodriguez G I; Loos W J; Hudson I; Broom C; Verweij J; Von Hoff D D
Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(3):1087-93.
-
1997: Schellens J H; Van de Vrie W; Loos W J; Kolker H J; Verweij J; Stoter G; Durante N M; Eggermont A M
Pharmacokinetics of the multidrug-resistance-converting drug dexniguldipine and its pyridine metabolite M-1 in the plasma, tumor, and renal tissue of tumor-bearing Wag/Rij rats.
Cancer chemotherapy and pharmacology 1997;41(1):48-52.
-
1996: Creemers G J; Gerrits C J; Schellens J H; Planting A S; van der Burg M E; van Beurden V M; de Boer-Dennert M; Harteveld M; Loos W; Hudson I; Stoter G; Verweij J
Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(9):2540-5.
-
1996: Loos W J; Stoter G; Verweij J; Schellens J H
Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine.
Journal of chromatography. B, Biomedical applications 1996;678(2):309-15.
-
1996: Ma J; Verweij J; Planting A S; Kolker H J; Loos W J; de Boer-Dennert M; van der Burg M E; Stoter G; Schellens J H
Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes.
Cancer chemotherapy and pharmacology 1996;37(4):382-4.
-
1994: Schellens J H; Planting A S; van Acker B A; Loos W J; de Boer-Dennert M; van der Burg M E; Koier I; Krediet R T; Stoter G; Verweij J
Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09.
Journal of the National Cancer Institute 1994;86(12):906-12.
-
1993: Schellens J H; Loos W; Beijnen J H; Stoter G; Verweij J
Sensitive isocratic high-performance liquid chromatographic determination of a novel indoloquinone cytotoxic drug (EO9) in human plasma and urine.
Journal of chromatography 1993;615(2):309-15.
Sign-in to see more
